로딩 중…
지수 로딩 중…
LENZ Therapeutics, Inc.
LENZ· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$4.07-1.45%
2026-09-18
Financials
Valuation Metrics
LENZ Therapeutics, Inc.'s Market Cap is $128M. At end of 2025 it was $457M. Ranked #3069 of 3,121 in US market (top 98%), #1419 of 1,463 on NASDAQ (top 97%), #263 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 99%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $128M | US#3,069/3,121 Sec#263/266 |
| Revenue | $21M | US#2,817/3,121 Sec#164/266 |
| Net Income | $-126M | US—/3,121 Sec—/266 |
| Total Assets | $237M | US#2,969/3,121 Sec#238/266 |
| Net Assets | $219M | US#2,656/3,121 Sec#183/266 |
| Employees | 152 | US#2,545/3,121 Sec#145/266 |
| Value | ||
| P/B | 0.58x | US#99/3,121 Sec#1/266 |
| P/S | 5.94x | US#2,439/3,121 Sec#87/266 |
| FCF Yield | -89.66% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -57.47% | US#2,711/3,121 Sec#167/266 |
| ROA | -53.26% | US#3,001/3,121 Sec#220/266 |
| Op. Margin | -631.70% | US#2,813/3,121 Sec#158/266 |
| Revenue Growth | 329.50% | US#41/3,121 Sec#18/266 |
| Financial Health | ||
| Debt Ratio | 7.91% | US#79/3,121 Sec#36/266 |
| Total Debt | $122000.00 | US#3,021/3,121 Sec#260/266 |
| FCF | $-114M | US#2,656/3,121 Sec#154/266 |
| Cash | $24M | US#2,822/3,121 Sec#254/266 |
| Current Ratio | 13.55x | US#188/3,121 Sec#58/266 |
| Performance | ||
| 1Y Return | -90.24% | US#3,124/3,121 Sec#266/266 |
| 1M Return | -17.28% | US#2,716/3,121 Sec#208/266 |
| From 52W High | -91.92% | US#3,120/3,121 Sec#267/266 |
| 1Y MDD | -91.70% | US#3,121/3,121 Sec#266/266 |
| Trading | ||
| Volume | 649,076 shares | US#1,512/3,121 Sec#165/266 |
| Trading Value | $3M | US#2,759/3,121 Sec#233/266 |
| Per Share | ||
| EPS | $-4.02 | US—/3,121 Sec—/266 |
| BPS | $6.99 | US#2,091/3,121 Sec#100/266 |
Company Info
LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States. The company's portfolio features two investigational products, LNZ100 and LNZ101, both of which are currently undergoing late-stage Phase III clinical trials as potential solutions for presbyopia. Corporate operations for LENZ Therapeutics are situated in Del Mar, California.